C17-Substituted Neuroactive Steroids for GABA Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with low progesterone levels, such as premenstrual syndrome (PMS), catamenial epilepsy, and postnatal depression, are inadequate, as existing therapies like progesterone are not consistently effective and do not establish a clear dose-response relationship.
Innovation Solution
Development of C17-substituted neuroactive steroids that act as GABA modulators, designed to induce anesthesia, sedation, and treat various CNS-related disorders, including epilepsy, by administering compounds of specific formulas that interact with GABA receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If progesterone is administered to treat conditions associated with low progesterone levels, then therapeutic effects are achieved, but the treatment is not consistently effective and does not establish a clear dose-response relationship
Solution Approach 1:
The patent modifies the chemical structure of progesterone by introducing substitutions at the C17 position, creating derivatives with altered pharmacological properties. This structural parameter change aims to improve treatment consistency and establish clearer dose-response relationships by optimizing the molecular characteristics of the neuroactive steroid
Solution Approach 2:
The invention creates composite molecular structures by combining the progesterone core with additional functional groups at the C17 position. These composite steroid structures integrate multiple pharmacophores that work synergistically to enhance therapeutic reliability and dosing predictability
2Reliability
If existing therapies are used for premenstrual syndrome, catamenial epilepsy, and postnatal depression, then some therapeutic benefit is provided, but the treatments are inadequate and not consistently effective
Solution Approach 1:
The patent alters key pharmacological parameters of progesterone through C17 substitution, modifying properties such as receptor affinity, metabolic stability, and neuroactive potency. These parameter changes aim to create more reliable and adequate treatments for PMS, catamenial epilepsy, and postnatal depression
3Reliability
If C17-substituted neuroactive steroids are developed to act as GABA modulators, then brain excitability is effectively modulated, but the complexity of the compound structure increases
Solution Approach 1:
The patent divides the steroid molecule into functional segments, with the C17 substituent representing a distinct pharmacophoric element that can be independently optimized. This segmentation allows systematic exploration of structure-activity relationships while maintaining reliable GABA modulation
Solution Approach 2:
The C17-substituted steroid structure serves multiple functions: it maintains the neuroactive steroid core activity, provides GABA receptor modulation, and offers a platform for further optimization. This multi-functionality achieves reliable brain excitability modulation while managing structural complexity through design efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The C17-substituted neuroactive steroids effectively modulate brain excitability, providing therapeutic benefits for conditions like epilepsy, PMS, and postnatal depression, offering alternative treatment options with potential for rapid onset of action.
Implementation Method 1
GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell. An intracellular increase in the levels of this anion causes hyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs
Data Source
AI summary
Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.